Nanotechnology Now

Our NanoNews Digest Sponsors
Heifer International

Wikipedia Affiliate Button

Home > Press > Iroko Selects Aptuit as Contract Manufacturing Partner for Phase III Lower-Dose NSAID Programs Formulated Using the SoluMatrix™ Nanotechnology Platform

Abstract:
Iroko Pharmaceuticals, LLC and Aptuit Inc. announced today that Aptuit will provide manufacturing scale-up services as Iroko progresses its novel pain medications to Phase III clinical trials.

Iroko Selects Aptuit as Contract Manufacturing Partner for Phase III Lower-Dose NSAID Programs Formulated Using the SoluMatrix™ Nanotechnology Platform

Philadelphia, PA and Greenwich, CT | Posted on May 4th, 2011

Under the services agreement, Aptuit will produce for Iroko Phase III supplies of lower dose, nanotechnology formulations for multiple nonsteroidal anti-inflammatory drugs (NSAIDs). Iroko has already completed Phase II studies for all of these products. Aptuit will also make batch material to satisfy requirements for product registrations.

While serving as a contract manufacturer, Aptuit will make use of the proprietary SoluMatrix™ technology of Iroko partner iCeutica Inc (recently acquired by Iroko on April 26, 2011 as announced in a previous press release). This nanoformulation technology makes possible the production of medications consisting of sub-micron, fast-dissolving drug particles.

John Vavricka, Iroko's Chief Executive Officer, commented, "Our strategic focus responds to the directive of the US Food and Drug Administration that NSAIDs should be used at the lowest effective dose for the shortest possible duration.1 We believe our patented nanoformulations will enable the development of NSAIDs at significantly lower doses without compromising onset of action or effectiveness. The consistent quality and attention to detail which Aptuit brings to its work will be an important resource as we advance these products toward the market."

"The confidence Iroko has placed in our ability to support them through this project as they progress their Phase III programs is a testament to the expertise of our team and the rigor of our science," said Timothy Tyson, Executive Chairman and Chief Executive Officer of Aptuit. "We look forward to working closely with Iroko to deliver a complete range of manufacturing services and to serve as a partner in advancing these important products."

####

About Iroko Pharmaceuticals, LLC
Iroko Pharmaceuticals, LLC is a pharmaceutical company committed to the development and commercialization of currently marketed pharmaceutical products in specialty therapeutic areas. Iroko is focused on the maximization of the revenue potential of these products through directed selling and marketing efforts and product-life-cycle management activities including development of new formulations to improve patient therapies. Iroko currently has several products under development using iCeutica's proprietary SoluMatrix™ Platform.

About Aptuit:
Aptuit Inc. is a global pharmaceutical services company focused on delivering contract development and manufacturing services and streamlining the drug development process for biotechnology and pharmaceutical innovators. Aptuit’s employees deliver an integrated suite of product development services to more than 800 companies worldwide, driven by a deep commitment to client service, quality and an unrivaled track record of scientific excellence. The company is partnered with Welsh, Carson, Anderson & Stowe, one of the world’s leading private equity investors. For more information about Aptuit, please visit www.aptuit.com, or for more information about Aptuit’s acquisition of the Verona Medicines Research Centre operations, please visit www.aptuit.com/Verona.

For more information, please click here

Contacts:
Iroko contact:
Phoenix IP Ventures
Lisa Gray, Managing Partner
267-765-3233

or
Aptuit contact:
Feinstein Kean Healthcare
Krystle Ficco
617-761-6702

Copyright © Business Wire

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Gold nanoparticles to facilitate in-situ detection of amplified DNA at room temperature March 21st, 2019

CEA-Leti Announces Prototype of Next-generation Photo-Acoustic Sensors for Gas Detection: REDFINCH Team Achieves These Capabilities in Mid-infrared Region, Where Many Important Chemical and Biological Species Have Strong Absorption Fingerprints March 21st, 2019

Fish-Inspired Material Changes Color Using Nanocolumns March 18th, 2019

New method to reduce uranium concentration in contaminated water March 18th, 2019

Nanomedicine

Gold nanoparticles to facilitate in-situ detection of amplified DNA at room temperature March 21st, 2019

Arrowhead Pharmaceuticals Begins Dosing in Phase 1 Study of ARO-APOC3 for Treatment of Hypertriglyceridemia March 11th, 2019

New optical imaging system could be deployed to find tiny tumors: Near-infrared technology pinpoints fluorescent probes deep within living tissue; may be used to detect cancer earlier March 8th, 2019

Computer-designed vaccine elicits potent antibodies against RSV: The nanoparticle platform for this respiratory syncytial virus study will be applied to vaccine research on flu, HIV, and more; Seattle startup Icosavax will advance related clinical trials March 8th, 2019

Announcements

Gold nanoparticles to facilitate in-situ detection of amplified DNA at room temperature March 21st, 2019

CEA-Leti Announces Prototype of Next-generation Photo-Acoustic Sensors for Gas Detection: REDFINCH Team Achieves These Capabilities in Mid-infrared Region, Where Many Important Chemical and Biological Species Have Strong Absorption Fingerprints March 21st, 2019

Fish-Inspired Material Changes Color Using Nanocolumns March 18th, 2019

New method to reduce uranium concentration in contaminated water March 18th, 2019

Alliances/Trade associations/Partnerships/Distributorships

CEA-Leti Announces Prototype of Next-generation Photo-Acoustic Sensors for Gas Detection: REDFINCH Team Achieves These Capabilities in Mid-infrared Region, Where Many Important Chemical and Biological Species Have Strong Absorption Fingerprints March 21st, 2019

Synopsys and GLOBALFOUNDRIES Collaborate to Develop Industry’s First Automotive Grade 1 IP for 22FDX Process: Synopsys’ Portfolio of DesignWare Foundation, Analog, and Interface IP Accelerate ISO 26262 Qualification for ADAS, Powertrain, 5G, and Radar Automotive SoCs February 22nd, 2019

CEA-Leti & Stanford Target Edge-AI Apps with Breakthrough Memory Cell: Paper at ISSCC 2019 Presents Proof-of-Concept Multi-Bit Chip That Overcomes NVM’s Read/Write, Latency and Integration Challenges February 20th, 2019

John Chong of Kionix Named Chair of MEMS & Sensors Industry Group Governing Council February 6th, 2019

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project